Clinical Trials

982 enrolled 15 charts

Prostatic Neoplasms

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

1,503 enrolled

Prostatic Neoplasms

NCT03875235 2026-03-19

TOPAZ-1

810 enrolled 24 charts 1 FDA

Gastrointestinal

Biliary Tract Neoplasms

NCT04338269 2026-03-19

CONTACT-03

Phase 3 Terminated

522 enrolled 22 charts

Carcinoma, Renal Cell

NCT04658862 2026-03-19

SunRISe-2

518 enrolled

Urinary Bladder Neoplasms

NCT04720716 2026-03-19

A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC

344 enrolled

Gastrointestinal

Carcinoma, Hepatocellular

NCT05232916 2026-03-19

FLAMINGO-01

750 enrolled

Breast Neoplasms, Neoplasm, Residual

NCT05714202 2026-03-19

SunRISe-3

1,135 enrolled

Urinary Bladder Neoplasms

NCT06463587 2026-03-19

Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)

264 enrolled

Myasthenia Gravis

NCT06629779 2026-03-19

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

900 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT06846671 2026-03-19

CaDAnCe-302

250 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06852222 2026-03-19

cAMeLot-2

Other hematologic neoplasm

600 enrolled

Leukemia, Myeloid, Acute

NCT06943872 2026-03-19

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07218380 2026-03-19

FORAGER-2

450 enrolled

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

NCT07258511 2026-03-19

TRIlogy-4

400 enrolled

Phase 3 Not yet recruiting

Multiple Myeloma

NCT07286266 2026-03-19

A Study to Investigate GSK5733584 Compared With Chemotherapy in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)

450 enrolled

Gynecologic

Ovarian Neoplasms

NCT07349069 2026-03-19

A Phase III Trial Comparing HRS-8080 With Standard Endocrine Therapy in Patients With High-Risk Early Breast Cancer

4,800 enrolled

Breast Neoplasms

NCT00099437 2026-03-18

CONFIRM

736 enrolled 14 charts

Breast Neoplasms

NCT02838420 2026-03-18

A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

187 enrolled 14 charts

Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer

NCT02973789 2026-03-18

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

291 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung

NCT03301220 2026-03-18

A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma

390 enrolled 12 charts 1 FDA

Smoldering Multiple Myeloma

NCT04379635 2026-03-18

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

453 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04948333 2026-03-18

Asciminib Treatment Optimization in ≥ 3rd Line CML-CP

MyeloidOther hematologic neoplasm

199 enrolled 13 charts

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT05083169 2026-03-18

MajesTEC-3

587 enrolled 1 FDA

Multiple Myeloma

NCT05100862 2026-03-18

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05629585 2026-03-18

A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

1,174 enrolled

Breast Neoplasms

NCT05654623 2026-03-18

VERITAC-2

624 enrolled 17 charts

Breast Neoplasms

NCT06012435 2026-03-18

A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer

703 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms

NCT06151574 2026-03-18

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT06496178 2026-03-18

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

500 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06510374 2026-03-18

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06549595 2026-03-18

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

1,018 enrolled

Lymphoma, Follicular

NCT06970847 2026-03-18

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT06973187 2026-03-18

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

500 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06980480 2026-03-18

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

183 enrolled

Multiple Myeloma

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07205822 2026-03-18

TB06

100 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07277231 2026-03-18

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

500 enrolled

Phase 3 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07480356 2026-03-18

ADVANCED-3

284 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT02504372 2026-03-17

PEARLS

1,177 enrolled 21 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT02947347 2026-03-17

Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma

445 enrolled 18 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT04404283 2026-03-17

ECHELON-3

238 enrolled 1 FDA

Lymphoma, Large B-Cell, Diffuse

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT05552976 2026-03-17

SUCCESSOR-2

525 enrolled

Multiple Myeloma, Recurrence

NCT05794906 2026-03-17

ARASTEP

985 enrolled

Biochemically Recurrent Prostate Cancer

NCT06072781 2026-03-17

RAMP 301

270 enrolled

Gynecologic

Low Grade Serous Ovarian Cancer

NCT06211764 2026-03-17

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled